About: http://data.cimple.eu/news-article/f1309538b2ea6d403c3cccf0d2b0fa429f7dc546e2a3640abd7555ce

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/f1309538b2ea6d403c3cccf0d2b0fa429f7dc546e2a3640abd7555ce Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	Pfizer and BioNTech said Thursday they are studying adding a third dose to their vaccine regime and testing a new version targeting the South African variant of the coronavirus. As countries around the world rush to vaccinate people, concerns have risen that more transmissible variants such as the one first detected in South Africa or another in Britain are more resistant to existing vaccines. In one study, the US and German pharmaceutical firms said they would look at what happens when people are given a third dose of their two-shot vaccine, six to 12 months after the booster. They said in a statement they are also talking to regulators about testing a modified version of their original vaccine to address the South African variant known as B.1.351. "We are taking multiple steps to act decisively and be ready in case a strain becomes resistant to the protection afforded by the vaccine," Dr. Albert Bourla, Pfizer's CEO, said in a statement. The South African variant is considered among the more dangerous of current mutations because it evades some of the blocking action of antibodies that target the older coronavirus strain. That means people who were infected with the classic strain are more susceptible to reinfection, and research has also shown the variant has partly reduced the protection of the current generation of vaccines. Moderna, the other company whose vaccine has been approved for emergency use in America, said Wednesday that doses of its new Covid-19 vaccine candidate aimed at the South African coronavirus variant had been shipped to the US National Institutes of Health for testing. dw/ec
schema:headline	Pfizer to test third dose, tweaked vaccine to target S.African strain
schema:mentions	Deutsche Welle Medication Antibody South Africa Chief executive officer Pfizer Vaccine Coronavirus Coronavirus disease 2019 Version targeting EC (programming language)
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2021-02-25 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	positive sentiment
http://data.cimple...readability_score	81 (xsd:integer)

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 5 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software